Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 367 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06066580Enrolling by invitationPhase 2
Long-term sevasemten study for Becker muscular dystrophy
This trial offers continued treatment with sevasemten (EDG-5506) for people with Becker muscular dystrophy who already completed a previous study of this drug. It tests the long-term safety and effects of taking sevasemten over more time.
Little Rock, ArkansasAges Any age - NCT05494398Enrolling by invitationPhase 2/Phase 3
Testing N-acetylcysteine for autism symptoms
This study looks at whether N-acetylcysteine (NAC), a supplement/medication, can help autism-related symptoms by trying to target brain chemistry. You may be able to join if you previously took part in a related NAC study and can keep your usual medications steady.
Stanford, CaliforniaAges 3–13 - NCT05441475Enrolling by invitationPhase 2
Trial for advanced liver cancer using ABSK-011 plus atezolizumab
This Phase 2 study tests ABSK-011 combined with either atezolizumab or the usual care in people with advanced or unresectable liver cancer. It aims to see if the treatment helps shrink tumors and control the cancer when standard options aren’t working or can’t be used.
Hubei, Shanghai MunicipalityAges 18 years+ - NCT05426733Enrolling by invitationPhase 3
Long-term extension study of odevixibat for biliary atresia
This study follows children with biliary atresia who finished an earlier 104-week treatment study, to check how well odevixibat works over the long term and whether it remains safe. If you completed the prior study, this extension may be an option to continue monitoring and treatment.
Aurora, ColoradoAges Any age - NCT04933721Enrolling by invitationPhase 3
Continue berotralstat for people with hereditary angioedema
This study lets people who were already taking berotralstat through earlier BioCryst studies keep the treatment going. It looks at safety and ongoing benefit for preventing hereditary angioedema attacks.
OttawaAges 2 years+ - NCT04848506Enrolling by invitationPhase 2/Phase 3
Long-term safety follow-up with aficamten for adults with HCM
This study checks how safe and well-tolerated aficamten is over the long run in adults with hypertrophic cardiomyopathy (HCM). You may be eligible if you finished a prior Cytokinetics aficamten study and your heart pumping strength is in the required range.
Birmingham, AlabamaAges 18–85 - NCT03683186Enrolling by invitationPhase 3
Long-term study of ralinepag for pulmonary hypertension
This study follows people with pulmonary arterial hypertension (PAH) to see how safe and effective ralinepag is over the long term. It may help your care team understand what to expect from continued treatment and monitoring.
Phoenix, ArizonaAges 18 years+
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 367 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.